Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Mocertatug rezetecan |
| Trade Name | |
| Synonyms | GSK 5733584|GSK-5733584|HS-20089|GSK5733584 |
| Drug Descriptions |
Mocertatug rezetecan (GSK5733584) is an antibody-drug conjugate (ADC) comprising a monoclonal antibody targeting VTCN1 (B7-H4) linked to a topoisomerase I inhibitor, which potentially induces apoptosis in VTCN1 (B7-H4)-expressing tumor cells (Cancer Res (2025) 85 (8_Supplement_2): CT188, NCI Drug Dictionary). |
| DrugClasses | B7-H4 (VTCN1) Antibody 13 |
| CAS Registry Number | NA |
| NCIT ID | C210991 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Bevacizumab + Dostarlimab-gxly + Mocertatug rezetecan | Bevacizumab Dostarlimab-gxly Mocertatug rezetecan | 0 | 0 |
| Bevacizumab + Mocertatug rezetecan | Bevacizumab Mocertatug rezetecan | 0 | 2 |
| Dostarlimab-gxly + Mocertatug rezetecan | Dostarlimab-gxly Mocertatug rezetecan | 0 | 2 |
| Mocertatug rezetecan | Mocertatug rezetecan | 0 | 4 |